Furthermore, using an in vivo model, they found that the combination of PD-1/PD-L1 blockade with an epigenetic modulator improves the trafficking of CD8+ T-cells into tumor tissues and promotes tumor regression. This evidence concerns the gene CD8A and neoplasm.